CN1169570C - Medicine for treating acute and chronic hepatitis B - Google Patents
Medicine for treating acute and chronic hepatitis B Download PDFInfo
- Publication number
- CN1169570C CN1169570C CNB021384312A CN02138431A CN1169570C CN 1169570 C CN1169570 C CN 1169570C CN B021384312 A CNB021384312 A CN B021384312A CN 02138431 A CN02138431 A CN 02138431A CN 1169570 C CN1169570 C CN 1169570C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- present
- liver
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine for treating acute and chronic hepatitis B, which is prepared from eleven kinds of traditional Chinese medicines, such as Radix Pseudostellariae, Faeces Togopteri, red sage root, chicken's gizzard-membrane, mongolian dandelion herb, membranous milkvetch root, Artemisia capillaris Thunb, glycyrrhiza, angelica, Radix Rehmanniae Preparata, etc. Through clinical observation for many years, after the medicine of the present invention is continuously taken for one course of treatment, the negative rate of HBsAg is 50%, the negative rate of HBeAg is 85%, the negative rate of HBV-DNA is 90%, and the recovery rate of liver functions is 96%. Anti-HBS of 10% of patients who can not be cured for many year is changed from a negative state into a positive state, and immune antibodies are acquired. When the medicine of the present invention is taken, immune cells and liver functions are adjusted; interferon in human bodies is generated, and virus replication in the liver is difficult; viral genes HBV-DNA are killed, the combination of new hepatitis B viruses in the liver is difficult, the medicine of the present invention does not have toxic or side effect, and the therapeutic effect is stable; the functions of activating blood circulation and removing stasis are achieved. The medicine of the present invention has good therapeutic effect on early liver cirrhosis, and after the medicine is taken for six months, the total effective rate reashes 98%.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of acute or chronic hepatitis B, specifically is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.
Background technology
China is hepatitis big country, and hepatitis b virus carrier accounts for the 10-20% of total population, and wherein 25% is chronic hepatitis B patient, sends out the patient based on person between twenty and fifty.Along with the unban population increase in density, the degree of crowding day by day increases, and the chance that hepatitis is propagated is more, and the sickness rate of hepatitis is higher.Chronic hepatitis B is a kind of chronic, infectious disease that is caused by hepatitis B virus (HBV), and serious harm health influences quality of life.Chronic hepatitis B is a kind of commonly encountered diseases, frequently-occurring disease.Can be divided into according to hepatitis B surface antigen (HBsAg) carrying rate: high popular district (＞8%), in popular district (2%-7%), low popular district (＜2%).China is one of high popular district.According to statistics, the present hepatitis B virus infection rate of China overview is: anti-HBc and/or anti-HBs positive person are about 60%; Non-infection population accounts for 26%; Chronic hepatitis B reaches 2%; The male chronic asymptomatic HBsAg carrier of HBsAg is 10%; The chronic asymptomatic HBV carrier of HBsAg feminine gender is 2%.This shows that the popular situation of China's hepatitis B is very severe.At present in the drug market, the medicine the most in fashion of treatment hepatitis B is " lamivudine-heptodin ", but its defective be bounce soon, virus variation easily starts an inflammation of the liver; Interferon is arranged again, and its defective is that negative conversion rate is low, and a few peoples can cause that the paddy third ammonia enzyme raises, and patient is difficult to accept.
Summary of the invention
The technical problem to be solved in the present invention is, proposed a kind of respond well medicine of acute or chronic hepatitis B for the treatment of, and it is to the big and small three Yang negative conversion rate height of hepatitis B patient, and is without any side effects.
Hepatitis B is current national brainstorm project, and Western medicine still can't thoroughly solve, but Chinese medicine gets a good chance of.Causing the reason that disease can not rehabilitation mainly is that human body is weakened body resistance, autoimmune function is low, can not resist, dispel virus, and some human autoimmune is regulated disorderly in addition, or incoordination of seven emotions or battalion food do not save, or drink or tired or sexual strain all can increase the weight of the prolonged of the state of an illness and do not heal.The opinion of disease such as ancient times many well-known doctor Dui Yu lumps in the chest and abdomen, yellow dawn, tympanites is controlled, can be the hepatitis B of today summary wherein.Temperature, clear, disappear, benefit, antiperspirant, tell, down and method of treatment a lot, " life-gate theory ", " Treatise on the spleen and stomach " main benefit are more arranged, the argument of " antiperspirant, tell, down " main attack, and the inventor conscientiously learns to the sage of the past, gets its length, and in conjunction with modern medicine theory and clinical practice, with treatment must aim at the pathogenesis of disease, strengthening vital QI to eliminate pathogenic factors is a principle, adopts flat filling blood and stops up stagnant, heat-clearing and toxic substances removing and not absurd throwing bitter cold, blood circulation promoting and dispersing pathogen accumulation and the general plan of gently sending an expedition against, and prescription forms.
The technical problem to be solved in the present invention is achieved through the following technical solutions, and a kind of medicine for the treatment of acute or chronic hepatitis B is characterized in that it is the medicament of being made by following weight proportioning raw material:
Radix Pseudostellariae 15～25, Oletum Trogopterori 8～12, Radix Salviae Miltiorrhizae 6～10, Endothelium Corneum Gigeriae Galli 6～8, Herba Taraxaci 10～15, the Radix Astragali 20～30, Herba Artemisiae Scopariae 25～30, Radix Glycyrrhizae 10～12, Fructus Aurantii 5～8, Radix Angelicae Sinensis 10～15, Radix Rehmanniae Preparata 12～20.
The technical problem to be solved in the present invention can also further be reached by following technical scheme, and the optimum weight of medicine of the present invention (part) proportioning is:
Radix Pseudostellariae 20, Oletum Trogopterori 8, Radix Salviae Miltiorrhizae 6, Endothelium Corneum Gigeriae Galli 6, Herba Taraxaci 10, the Radix Astragali 20, Herba Artemisiae Scopariae 30, Radix Glycyrrhizae 10, Fructus Aurantii 5, Radix Angelicae Sinensis 10, Radix Rehmanniae Preparata 12.
The technical problem to be solved in the present invention can also further be reached by following technical scheme, and the said medicament of the present invention is a said dosage form on any pharmaceutics.
The technical problem to be solved in the present invention can also further be reached by following technical scheme, and the said medicament of the present invention is a decoction.
As everyone knows, the pathogenic former of hepatitis B is hepatitis B virus.After hepatitis B virus is survived in hepatocyte, is duplicated.Be discharged in the blood again, thus viral high load capacity in the blood flow not only, and also most of hepatocyte of liver are all infected.HBV itself does not directly cause hepatocellular pathological changes, just survives in hepatocyte, duplicates, and the antigen presentation that it duplicated is on liver plasma membrane, and the immune system of exciting human is recognized, and cleaning reaction is taken place.But behind the human infection hepatitis B virus, because the body's immunity difference, thereby course of disease development is also different.If body's immunological function is sound, the immune system back identification hepatitis B virus that is activated is attacked the hepatocyte of infective virus and is removed it; If body's immunological function is activated, but be in low state, body is attacked repeatedly to the hepatocyte of infective virus, but can not remove it fully again, causes the hepatic tissue chronic inflammatory disease to be shown effect repeatedly, Here it is chronic viral hepatitis B; If body's immunological function is in tolerance status, can not discern hepatitis B virus, therefore do not attack the hepatocyte of infective virus, virus and human body " peaceful coexistence ", Here it is hepatitis B virus carriers.Hepatitis B virus infection person state of an illness difference, Therapeutic Method also is different.Acute hepatitis b should early be found, early treatment is main to the Supporting Therapy of suiting the medicine to the illness, and fully has a rest, and reasonable diet is avoided tobacco and wine, and avoiding PD is hepatitis gravis or chronic hepatitis; Chronic viral hepatitis B, the treatment measure comprises antiviral therapy, immune modulating treatment, psychology, symptomatic treatment etc.Think at present,, continue development and may cause liver cirrhosis and HBV dependency hepatocarcinoma, so antiviral therapy is the key for the treatment of chronic hepatitis B because the persistent infection of virus causes the hepatitis chronicity.The purpose for the treatment of chronic hepatitis B is: 1) suppress virus replication, promote virus sweep; 2) alleviate liver inflammation and necrosis, promote hepatocyte to repair; 3) prevention or delay of progression are liver cirrhosis; 4) incidence rate of minimizing HBV dependency hepatocarcinoma; 5) improve quality of life of patient, prolong life cycle; 6) alleviate, alleviate clinical symptoms.
Side's medicine of the present invention, wherein Radix Pseudostellariae, Radix Rehmanniae Preparata fill blood, and strengthen the liver cell regeneration ability, repair hepatic injury, strengthen human leukocytes and immunologic function; The Radix Astragali can promote human body to produce interferon simply, and strong inhibition hepatitis B virus and HBV-DNA duplicate; Herba Artemisiae Scopariae, Herba Taraxaci all have the effect of good detoxifcation, antiinflammatory, depressed liver-energy dispersing and function of gallbladder promoting; Radix Glycyrrhizae is rich in glycyrrhizin, falls enzyme and has better effect; Adapted Radix Salviae Miltiorrhizae, Fructus Aurantii, Oletum Trogopterori, Radix Angelicae Sinensis dispersing the stagnated live-QI to relieve the stagnation of QI, blood circulation promoting and blood stasis dispelling is just accord with " interior warp " institute cloud: the meaning of " liver preferring free activity ".The same usefulness of all medicines can reach every index of recovering liver function, removes hepatitis B virus gene HBV-DNA, promotes HBsAg, HBeAg sun to turn out cloudy.
Side's medicine of the present invention can be by the Chinese medicine conventional method through being decocted in water for oral dose, and be three to six months a course of treatment, do not have taboo, the patient taken other medicines simultaneously do not have influence.
Side's medicine of the present invention shows through clinical practice for many years, and square medicine is taken course of treatment of our medicine continuously, and the HBsAg negative conversion rate is 50%, the HBeAg negative conversion rate is 85%, the HBV-DNA negative conversion rate is 90%, and the liver function recovery natural rate of interest is 96%.There is 10% patient not produce the cloudy sun that changes of anti-HBS for many years more again, obtains immunity (antibody).Take side's medicine of the present invention, 1, regulate immunocyte and liver function; 2, human activin produces interferon, causes the virus replication difficulty of liver inside; 3, kill virus gene HBV-DNA makes and is difficult to make up new hepatitis B virus, without any side effects and stable curative effect in the liver; 4, blood circulation promoting and dispersing pathogen accumulation.Especially good to the early stage liver cirrhosis therapeutic effect, take six months after, total effective rate is 98%.
The specific embodiment
Embodiment one, takes by weighing raw material by following proportioning:
Radix Pseudostellariae 20g, Oletum Trogopterori 8g, Radix Salviae Miltiorrhizae 6g, Endothelium Corneum Gigeriae Galli 6g,
Herba Taraxaci 10g, Radix Astragali 20g, Herba Artemisiae Scopariae 30g, Radix Glycyrrhizae 10g,
Fructus Aurantii 5g, Radix Angelicae Sinensis 10g, Radix Rehmanniae Preparata 12g.
This is one pair of medicine, by the Chinese medicine conventional method through being decocted in water for oral dose.
The present invention extracts its effective ingredient after also can decocting
The present invention also can clean, dries, concoct post-treatment and become powder at crude drug, dress up capsule by above-mentioned crude drug dosage and take.In addition, the present invention extracts its effective ingredient after also can decocting, and makes dissolved granule and takes.
Embodiment two, take by weighing raw material by following proportioning:
Radix Pseudostellariae 15g, Oletum Trogopterori 10g, Radix Salviae Miltiorrhizae 8g, Endothelium Corneum Gigeriae Galli 7g,
Herba Taraxaci 12g, Radix Astragali 25g, Herba Artemisiae Scopariae 28g, Radix Glycyrrhizae 11g,
Fructus Aurantii 6g, Radix Angelicae Sinensis 12g, Radix Rehmanniae Preparata 16g.
This is one pair of medicine, by the Chinese medicine conventional method through being decocted in water for oral dose.
Embodiment two, take by weighing raw material by following proportioning:
Radix Pseudostellariae 25g, Oletum Trogopterori 12g, Radix Salviae Miltiorrhizae 10g, Endothelium Corneum Gigeriae Galli 8g,
Herba Taraxaci 15g, Radix Astragali 30g, Herba Artemisiae Scopariae 25g, Radix Glycyrrhizae 12g,
Fructus Aurantii 8g, Radix Angelicae Sinensis 15g, Radix Rehmanniae Preparata 20g.
This is one pair of medicine, by the Chinese medicine conventional method through being decocted in water for oral dose.
Claims (3)
1. medicine for the treatment of acute or chronic hepatitis B is characterized in that it is the medicament of being made by following weight proportioning raw material:
Radix Pseudostellariae 15～25, Oletum Trogopterori 8～12, Radix Salviae Miltiorrhizae 6～10, Endothelium Corneum Gigeriae Galli 6～8,
Herba Taraxaci 10～15, the Radix Astragali 20～30, Herba Artemisiae Scopariae 25～30, Radix Glycyrrhizae 10～12,
Fructus Aurantii 5～8, Radix Angelicae Sinensis 10～15, Radix Rehmanniae Preparata 12～20.
2. the medicine of treatment acute or chronic hepatitis B according to claim 1 is characterized in that the weight proportion of medicine is:
Radix Pseudostellariae 20, Oletum Trogopterori 8, Radix Salviae Miltiorrhizae 6, Endothelium Corneum Gigeriae Galli 6,
Herba Taraxaci 10, the Radix Astragali 20, Herba Artemisiae Scopariae 30, Radix Glycyrrhizae 10,
Fructus Aurantii 5, Radix Angelicae Sinensis 10, Radix Rehmanniae Preparata 12.
3. the medicine of treatment acute or chronic hepatitis B according to claim 1 and 2 is characterized in that: said medicament is a decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021384312A CN1169570C (en) | 2002-10-11 | 2002-10-11 | Medicine for treating acute and chronic hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021384312A CN1169570C (en) | 2002-10-11 | 2002-10-11 | Medicine for treating acute and chronic hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1403140A CN1403140A (en) | 2003-03-19 |
| CN1169570C true CN1169570C (en) | 2004-10-06 |
Family
ID=4749477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021384312A Expired - Fee Related CN1169570C (en) | 2002-10-11 | 2002-10-11 | Medicine for treating acute and chronic hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1169570C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101502589B (en) * | 2009-03-11 | 2010-10-13 | 张建云 | Chinese and western medicinal composition containing bifendate for auxiliary treatment of hepatitis |
| CN103734430A (en) * | 2014-01-10 | 2014-04-23 | 蒋宇杰 | Health-maintenance healthcare tea for healing diseases by gene regulation |
| CN106421640A (en) * | 2016-10-14 | 2017-02-22 | 单县领翔金银花种植合作社 | Traditional Chinese medicine for curing hepatitis B in pregnancy |
| CN115192640A (en) * | 2021-04-12 | 2022-10-18 | 牛兴旺 | Traditional Chinese medicine for circularly treating viral infection |
-
2002
- 2002-10-11 CN CNB021384312A patent/CN1169570C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1403140A (en) | 2003-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101028507A (en) | Chinese-medicinal composition for treating asthma | |
| CN1475229A (en) | Antifatigue compound Chinese medicine prescription and its preparation method | |
| CN1698812A (en) | Pharmaceutical composition for treating hepatitis B | |
| CN1169570C (en) | Medicine for treating acute and chronic hepatitis B | |
| CN102552512B (en) | Traditional Chinese medicine used for treating hepatitis B | |
| CN1965979A (en) | Medicament for treating hepatitis B | |
| CN101199749A (en) | Chinese medicine for treating AIDS | |
| CN103479835A (en) | Traditional Chinese medicine for treating liver cirrhosis | |
| CN102488851B (en) | Drug for treating recurrent genital herpes and preparation method thereof | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN101618156A (en) | Medicine composition for treating hepatitis B and preparation method thereof | |
| CN102406906A (en) | Traditional Chinese medicine composition for treating acute hepatitis B | |
| CN103272183B (en) | Traditional Chinese medicine for treating hepatitis B induced cirrhosis | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof | |
| CN102935183B (en) | Children virus pneumonia treatment decoction | |
| CN102274438A (en) | Oral powder for treating hepatitis B | |
| CN1340353A (en) | Orally-applied medicine for treating hepatism and its preparing process | |
| CN1086949C (en) | Chinese medicine for hepatitis B and its preparation | |
| CN1965987A (en) | Chinese medicine for treating AIDS | |
| CN1085548C (en) | Traditional Chinese medicinal prepns. for treating hepatitis B virus, and method for preparing same | |
| CN1943682A (en) | A Chinese traditional medicinal composition for treatment of hepatitis C | |
| CN1279074A (en) | Chinese-medicinal pill 'Ganxuetong' | |
| CN1241591C (en) | Taiyi liver protection capsule and its preparing method | |
| CN1209131C (en) | Medicine 'Yiganjiangmeisan' for treating hepatitis B and its preparing process | |
| CN102266531A (en) | Medicine for treating hepatitis B |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041006 Termination date: 20091111 |